{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:52:39Z","timestamp":1790859159479,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bcp.2026.117828","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:14:09Z","timestamp":1771658049000},"page":"117828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe and enhances cisplatin sensitivity"],"prefix":"10.1016","volume":"248","author":[{"given":"Xiaoli","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baokun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ming","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.117828_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41416-020-0831-9","article-title":"Trends in cervical cancer incidence in sub-Saharan Africa","volume":"123","author":"Jedy-Agba","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117828_b0015","doi-asserted-by":"crossref","DOI":"10.34172\/jrhs.2022.87","article-title":"Evaluation of Survival Rate and Associated Factors in patients with Cervical Cancer: a Retrospective Cohort Study","volume":"22","author":"Tabatabaei","year":"2022","journal-title":"J Res Health Sci."},{"issue":"10421","key":"10.1016\/j.bcp.2026.117828_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.bcp.2026.117828_b0025","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117828_b0030","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN Guidelines(R) Insights: Cervical Cancer, Version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.bcp.2026.117828_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae023","article-title":"Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer","volume":"25","author":"Zang","year":"2024","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.bcp.2026.117828_b0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev.pharmtox.010909.105844","article-title":"The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer","volume":"50","author":"Drygin","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117828_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020266","article-title":"Targeting the RNA Polymerase I Transcription for Cancer Therapy comes of Age","volume":"9","author":"Ferreira","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2026.117828_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrc.2018.3","article-title":"Corrigendum: Ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.bcp.2026.117828_b0055","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1158\/0008-5472.CAN-09-1304","article-title":"Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis","volume":"69","author":"Drygin","year":"2009","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117828_b0060","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.117828_b0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in patients with Advanced Hematologic Cancers: results of a phase I Dose-Escalation Study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117828_b0070","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13(1):3607","author":"Hilton","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117828_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100856","article-title":"A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer","volume":"35","author":"Chung","year":"2023","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0080","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-021-26640-x","article-title":"The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.117828_b0085","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","article-title":"CX-5461 Sensitizes DNA damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition","volume":"20","author":"Lawrence","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0090","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41467-020-16393-4","article-title":"CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer","volume":"11","author":"Sanij","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.117828_b0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-022-01222-w","article-title":"The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma","volume":"40","author":"Kang","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.117828_b0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.actbio.2018.08.035","article-title":"CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy","volume":"79","author":"Duo","year":"2018","journal-title":"Acta Biomater."},{"issue":"10","key":"10.1016\/j.bcp.2026.117828_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101429","article-title":"The Targeting of RNA Polymerase I Transcription using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers","volume":"11","author":"Ismael","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2026.117828_b0110","doi-asserted-by":"crossref","first-page":"C1523","DOI":"10.1152\/ajpcell.00460.2011","article-title":"Mechanical loading induces the expression of a Pol I regulon at the onset of skeletal muscle hypertrophy","volume":"302","author":"von Walden","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2026.117828_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.dnarep.2014.04.008","article-title":"DNA-PK phosphorylation of RPA32 Ser4\/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe","volume":"21","author":"Ashley","year":"2014","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.bcp.2026.117828_b0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc2824","article-title":"Translational control in cancer","volume":"10","author":"Silvera","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.bcp.2026.117828_b0130","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1080\/15384101.2016.1215385","article-title":"Mammary epithelial morphogenesis and early breast cancer. evidence of involvement of basal components of the RNA Polymerase I transcription machinery","volume":"15","author":"Rossetti","year":"2016","journal-title":"Cell Cycle"},{"issue":"11","key":"10.1016\/j.bcp.2026.117828_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115782","article-title":"CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA damage and Replication stress in Triple-negative Breast Cancer","volume":"22","author":"Makhale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12967-025-06473-8","article-title":"The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117828_b0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","article-title":"The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer","volume":"124","author":"Yan","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2026.117828_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37227","article-title":"Molecular basis of CX-5461-induced DNA damage response in primary vascular smooth muscle cells","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"15","key":"10.1016\/j.bcp.2026.117828_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153819","article-title":"Proteins from the DNA damage Response: Regulation, Dysfunction, and Anticancer strategies","volume":"13","author":"Molinaro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-09-0938","article-title":"The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106","volume":"9","author":"Walton","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.bcp.2026.117828_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214258","article-title":"Newly Synthesized Melphalan Analogs Induce DNA damage and Mitotic catastrophe in Hematological Malignant Cancer Cells","volume":"23","author":"Poczta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117828_b0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2026.117828_b0175","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.apsb.2022.03.020","article-title":"Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.117828_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115289","article-title":"Co-inhibition of Aurora a and Haspin kinases enhances survivin blockage and p53 induction for mitotic catastrophe and apoptosis in human colorectal cancer","volume":"206","author":"Lin","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117828_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216970","article-title":"Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia","volume":"593","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0190","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1038\/s41598-017-09983-8","article-title":"Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0195","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1038\/s41598-022-07928-4","article-title":"CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I","volume":"12","author":"Lehman","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.117828_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13062-021-00313-7","article-title":"A link between mitotic defects and mitotic catastrophe: detection and cell fate","volume":"16","author":"Sazonova","year":"2021","journal-title":"Biol. Direct"},{"issue":"14","key":"10.1016\/j.bcp.2026.117828_b0205","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/emboj.2010.112","article-title":"Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest","volume":"29","author":"Harley","year":"2010","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bcp.2026.117828_b0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/onc.2008.369","article-title":"Generation of an indestructible cyclin B1 by caspase-6-dependent cleavage during mitotic catastrophe","volume":"28","author":"Chan","year":"2009","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bcp.2026.117828_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036372","article-title":"Mechanism of cancer cell death induced by depletion of an essential replication regulator","volume":"7","author":"Ito","year":"2012","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.bcp.2026.117828_b0220","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.bcp.2026.117828_b0225","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/sj.onc.1207573","article-title":"The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2026.117828_b0230","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/cercor\/bhx225","article-title":"alpha-Tubulin Acetylation Restricts Axon Overbranching by Dampening Microtubule Plus-End Dynamics in Neurons","volume":"28","author":"Dan","year":"2018","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.bcp.2026.117828_b0235","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/DDDT.S106412","article-title":"Molecular mechanisms of cisplatin resistance in cervical cancer","volume":"10","author":"Zhu","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2026.117828_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113345","article-title":"Cellular landscaping of cisplatin resistance in cervical cancer","volume":"153","author":"Bhattacharjee","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.bcp.2026.117828_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10608","article-title":"Cisplatin for cancer therapy and overcoming chemoresistance","volume":"8","author":"Ranasinghe","year":"2022","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.bcp.2026.117828_b0250","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200808RR","article-title":"CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT\/c-Myc-driven ribosome biogenesis","volume":"36","author":"Mohapatra","year":"2022","journal-title":"FASEB J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:00:43Z","timestamp":1777377643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S0006295226001590"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117828","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe and enhances cisplatin sensitivity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117828"}}